Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Fsd Pharma Inc Cl B
(CSE:
HUGE
)
0.4750
-0.0250 (-5.00%)
Official Closing Price
Updated: 3:59 PM EDT, May 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
29,440
Open
0.4900
Bid (Size)
0.4700 (2,000)
Ask (Size)
0.5000 (1,000)
Prev. Close
0.5000
Today's Range
0.4700 - 0.5100
52wk Range
0.3750 - 2.230
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
FSD Pharma Provides Corporate Update
May 24, 2024
Via
ACCESSWIRE
FSD Pharma Provides Update on Celly Nu's New Packaging for unbuzzd(TM)
May 16, 2024
Via
ACCESSWIRE
Performance
YTD
-62.00%
-62.00%
1 Month
-24.60%
-24.60%
3 Month
-62.89%
-62.89%
6 Month
-75.00%
-75.00%
1 Year
-65.83%
-65.83%
More News
Read More
TechMediaBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Marks Important Step in Advancing Lucid-21-302
May 07, 2024
Via
Investor Brand Network
FSD Pharma Submits a Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia
May 07, 2024
Via
ACCESSWIRE
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Agreement to Conduct Clinical Trial to Assess Safety, Efficacy of unbuzzd(TM)
April 30, 2024
Via
Investor Brand Network
FSD Pharma Signs Agreement with Applied Science and Performance Institute (ASPI) to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of unbuzzd(TM) in an Induced State of Alcohol Intoxication
April 30, 2024
Via
ACCESSWIRE
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) Announces Celly Nu, Six+One Collaboration to Launch unbuzzd(TM)
April 25, 2024
Via
Investor Brand Network
FSD Pharma Provides Update from Celly Nu’s Partnership with Six+One for unbuzzd(TM)
April 25, 2024
Via
ACCESSWIRE
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) Issues Update on Celly Nu’s Pending Launch of unbuzzd(TM)
April 22, 2024
Via
Investor Brand Network
FSD Pharma Provides Another Update on Celly Nu's Anticipated Launch of unbuzzd(TM)
April 22, 2024
Via
ACCESSWIRE
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) Announces Expansion of Investigative Pipeline
April 17, 2024
Via
Investor Brand Network
FSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and Products
April 17, 2024
Via
ACCESSWIRE
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Releases Update on Celly Nu Investment
April 15, 2024
Via
Investor Brand Network
FSD Pharma Provides Update on its Investment in Celly Nutrition Corp., a Company Launching a Product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption
April 15, 2024
Via
ACCESSWIRE
FSD Pharma Announces Filing of Year-End 2023 Results
April 01, 2024
Via
ACCESSWIRE
InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Subsidiary Partners with iNGENu CRO to Initiate MS Clinical Study
March 27, 2024
Via
Investor Brand Network
FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults
March 27, 2024
Via
ACCESSWIRE
FSD Pharma: A Compelling Value Proposition As UNBUZZD™ Positions To Dominate The Alcohol-Detox Functional Beverage Market
March 14, 2024
Via
AB Newswire
FSD Pharma’s Stake In Functional Beverage, UNBUZZD™, Is A Transformational Asset…Here’s Why
March 12, 2024
Via
AB Newswire
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Takes First Step Toward Obtaining Permission for unbuzzd(TM) Phase-1b Clinical Trial
March 11, 2024
Via
Investor Brand Network
FSD Pharma Submits a Phase-1b Clinical Trial Application for Ethics Committee for its Proprietary Beverage unbuzzd(TM)
March 11, 2024
Via
ACCESSWIRE
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Presents Positive Results on First-in-Human Phase 1 Study of Lucid-MS
March 05, 2024
Via
Investor Brand Network
FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum
March 05, 2024
Via
ACCESSWIRE
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Board of Directors Approves Debt Settlement
February 28, 2024
Via
Investor Brand Network
FSD Pharma Announces Debt Settlement
February 28, 2024
Via
ACCESSWIRE
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.